Media coverage about Alexion Pharmaceuticals (NASDAQ:ALXN) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.9577049685171 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- A Look at Ionis Pharmaceuticals’ January 2018 Valuation (finance.yahoo.com)
- Do What Institutional Investors Does: Occidental Petroleum Corporation (OXY), Alexion Pharmaceuticals, Inc. (ALXN) – Market Movers (financialqz.com)
- Alexion Pharmaceuticals, Inc. (ALXN) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
- Implied FBT Analyst Target Price: $151 – Nasdaq (nasdaq.com)
- Alexion Pharmaceuticals’ (ALXN) “Outperform” Rating Reiterated at Raymond James Financial (americanbankingnews.com)
Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded down $0.34 during mid-day trading on Wednesday, reaching $121.46. 1,434,357 shares of the company’s stock were exchanged, compared to its average volume of 2,170,000. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. Alexion Pharmaceuticals has a twelve month low of $96.18 and a twelve month high of $149.34. The company has a market cap of $27,140.00, a P/E ratio of 54.22, a P/E/G ratio of 1.03 and a beta of 1.17.
Several analysts have commented on the stock. UBS Group cut shares of Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Thursday, January 4th. Raymond James Financial reiterated an “outperform” rating and issued a $130.00 price target (down previously from $178.00) on shares of Alexion Pharmaceuticals in a research note on Thursday, January 4th. They noted that the move was a valuation call. Leerink Swann reiterated a “buy” rating and issued a $182.00 price target on shares of Alexion Pharmaceuticals in a research note on Monday, September 25th. BMO Capital Markets reiterated an “outperform” rating and issued a $173.00 price target (up previously from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Finally, SunTrust Banks reiterated a “buy” rating and issued a $180.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twenty have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $153.61.
In other news, CEO Ludwig Hantson sold 2,553 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now directly owns 36,172 shares in the company, valued at $4,399,600.36. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.35% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This article was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.com-unik.info/2018/01/10/alexion-pharmaceuticals-alxn-getting-somewhat-positive-media-coverage-report-shows.html.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.